Amgen (AMGN) Change in Receivables (2009 - 2026)

Amgen (AMGN) has reported Change in Receivables for 18 consecutive years, with -$413.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Receivables fell 131.57% year-over-year to -$413.0 million; the TTM figure through Mar 2026 stood at $955.0 million (down 29.42% YoY), while the FY2025 annual figure was $2.7 billion, up 706.8% from the prior year.
• Change in Receivables came in at -$413.0 million for Q1 2026 at Amgen, down from $1.1 billion in the prior quarter.
• The five-year high for Change in Receivables was $1.3 billion in Q1 2025, with the low at -$486.0 million in Q1 2024.
• Average Change in Receivables over 5 years is $210.8 million, with a median of $180.0 million recorded in 2022.
• Across the five-year window, Change in Receivables jumped 451.79% in 2022 and sank 437.5% in 2024, its largest moves.
• Year by year, Change in Receivables stood at $180.0 million in 2022, then soared by 140.56% to $433.0 million in 2023, then sank by 209.24% to -$473.0 million in 2024, then surged by 327.27% to $1.1 billion in 2025, then slumped by 138.42% to -$413.0 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$413.0 million, $1.1 billion, and -$222.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.